Now enrolling: the DESTINY study for adults with uncontrolled hypereosinophilic syndrome (HES)

A quick reference guide for patient advocacy groups

Thank you for your interest in learning about the DESTINY study. This fact sheet provides more details about the study that you can share with patients. If patients have any questions or would like to know more, please direct them to visit **www.gskdestinystudy.com**, scan the code on the back of this sheet, or call the local study site at the number on the back of this sheet.

What is this study?

The DESTINY clinical research study is looking for participants 18 years of age or older who are diagnosed with hypereosinophilic syndrome (HES) and have a history of 2 or more flares within the past 12 months. Study doctors are testing an investigational drug given as injections to find out if it works compared to a placebo and to determine the investigational drug's safety in people living with HES.

Some participants will receive the investigational drug (depemokimab) and some participants will receive a placebo. Both study groups will also receive standard of care HES therapy as prescribed by a doctor.

An investigational drug is one that is not approved for use by the general public. Placebo is a substance that looks like the study drug but has no active drug in it. Participants' study group assignment will be blinded, meaning neither they nor the study doctor will know which study group they are in.

Who is this study enrolling?

Approximately 120 participants will take part in this study. Patients may qualify for this study if they:

- Are at least 18 years of age or older
- Are diagnosed with HES
- Have a history of 2 or more flares within the past 12 months

Why is this study important?

HES is a rare, underdiagnosed condition that occurs when you have high numbers of eosinophils. Eosinophils are white blood cells that play an important role in your immune system. Inflammatory tissue damage and dysfunction can occur when eosinophils are overproduced for prolonged periods of time. People living with HES are in need of more effective therapies for this condition. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug (depemokimab) administered every 6 months compared to a placebo administered every 6 months.

How are the study drugs being tested?

In this study, participants will be assigned to a study drug group. They will receive either:

- An investigational drug (depemokimab) given as injections every 6 months (in addition to standard HES therapy as prescribed by a doctor)

OR

- A placebo drug given as injections every 6 months (in addition to standard HES therapy as prescribed by a doctor)

Participants will not be told which group they are in.

How long will this study last?

After the screening visit, participants will receive two injections every 6 months. This study will consist of at least 18 visits (in-clinic or remotely) over a period of up to 56 weeks plus a follow-up phone call 4 weeks after the final visit (additional visits may be necessary for HES flares).

How long is each study visit?

The duration of each visit can vary depending on the specific needs of each patient. Some visits may also be conducted at your home. Please ask your doctor for information about the duration of each visit based on your individual requirements.

How will participants' health be monitored in this study?

During the study, participants will visit the study site regularly for health checks and several types of tests and assessments. These may include:

- Physical exams
- Vital signs measurements (body temperature, blood pressure, and heart rate)
- Electrocardiograms (to measure the electrical activity of the heart)
- Echocardiogram (to check that the heart's valves and chambers are working properly)
- Spirometry (breathing tests to see how well the lungs work)
- Blood and urine tests
- Questionnaires from study staff and in the eDiary (at Visit 1, participants will be trained on how to use the eDiary at home to complete some questionnaires)

Not all of these activities will occur at every visit.

What are the benefits and risks of being in this study?

One benefit of taking part in this study is that participants' health will be monitored frequently. However, there is no guarantee that this study will improve a participant's health. It may stay the same or it may get worse. Also, as with all drugs, the study drugs may cause side effects. We may be able to prevent or manage some of these and many go away quickly. Any study has risks, which may include things that could make participants feel sick or uncomfortable or could cause harm. The study staff will review potential risks before study enrollment.

Is participating in this study mandatory?

Taking part in a clinical study is voluntary. Those eligible to enroll may choose to join the study but leave at a later date for any reason at any time. Regardless of whether a patient chooses to enroll or leave the study early, their future healthcare won't be affected.

How can patients learn more about this study?

To learn more, please direct patients to visit **www.gskdestinystudy.com**, scan the code below, or call our local study site at the number below. The study team can also schedule a screening appointment to explain the study in detail.

Study site phone number: _____

DESTINY